Lockheed Martin jumps into bionic suit market; Greatbatch shows off spinal cord stimulation device

 @FierceMedDev: FDA sticks Class I tag on Symbios' pump recall. Story | Follow @FierceMedDev

 @MarkHFierce: China's Dehaier Medical Systems will be one to watch in 2013 as it pursues govt. healthcare contracts at home. Story | Follow @MarkHFierce

 @DamianFierce: Third Rock Ventures-backed DC Devices hauled in another $10+ million for its heart failure device. More | Follow @DamianFierce

> NuVasive hit with FDA warning letter over spine device. More

> Johns Hopkins team takes step toward creating migraine blood Dx. Story

> Venture-backed Invuity has launched its minimally invasive visualization device, the Eigr Saber Waveguide. More

> Lockheed Martin ($LMT) is jumping into the market for bionic suits, competing in a field analysts say could be worth $400 million by 2020. Article

> Greatbatch ($GB) debuted its new spinal cord stimulation system for investors this week in New York. It's designed to treat pain. Story

> Researchers developing new medical technologies are looking to mimic nature in design and function. Story

> A Johnson & Johnson ($JNJ) sales rep indicted for reselling medical devices obtained from hospitals to which she previously sold the same products is spurring a U.S. Supreme Court case over whether the assets of a defendant can be frozen before trial. Item

> Implanting an endovascular stent into the sinus can help treat tinnitus and visual function, according to a study. Report

> Biomet is teaming up with OrthoSensor to co-promote the former's Vanguard Complete Knee System and the latter's Verasense, which can provide real-time knee kinetic data to surgeons. Release

Biotech News

 @FierceBiotech: FDA staff review raises big questions about fate of Titan's Probuphine. More | Follow @FierceBiotech

 @JohnCFierce: Biopharma's Top R&D Spenders - 2012. Special Report | Follow @JohnCFierce

 @RyanMFierce: Fierce's top 5 feats in life sciences 'gamification'. Special Report | Follow @RyanMFierce

> FDA staff review raises big questions about fate of Titan's Probuphine. More

> One foot in biotech graveyard, NeuroSearch is calling it quits. Article

> NPS Pharma goes global with $80M deal to buy back Gattex rights. Story

Pharma News

 @FiercePharma: Have generics reached a saturation point? With 84% utilization, maybe. And specialty prices are soaring. Article | Follow @FiercePharma

 @EricPFierce: 600,000 bottles of Glenmark's generic Singulair recalled for fishy smell. Recalls for odors not a rarity. Article | Follow @EricPFierce

> Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy. News

> Senator questions Pfizer's $2,000-a-month price on Xeljanz. Report

> Big Pharma drools after $25B market for pricey pet care. More

Biotech Research News

 @EmilyMFierce: Not to alarm anyone, but new research suggests that the black plague may still be a threat today. Post | Follow @EmilyMFierce

> Protein points to hormone therapy-resistant prostate cancer. Report

> Stem cell treatment could accelerate diabetic wound healing. Story

> Mount Sinai gets $5M from NIH to study neurological voice condition. Item

> Scripps, Takeda renew pact to find CNS treatments. More

Pharma Manufacturing News

> Claris a buyout candidate as shortages remake injectables biz. Item

> AmerisourceBergen gets Walgreen, Boots biz. Story

> FDA now inspecting 'high risk' compounders. News

> Lilly warehouse thieves followed risk-assessment 'road map.' Report

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.